Zhejiang Sunflower Great Health Co Ltd (300111.SZ), formerly Zhejiang Sunflower Great Health LLC and changed to its current name in December 2023, principally engages in the research, development, production and sales of pharmaceutical products focused on anti-infective, cardiovascular and digestive system drugs; key offerings include clarithromycin active pharmaceutical ingredient and tablets, azithromycin dispersible tablets and for injection, roxithromycin capsules, lacidipine dispersible tablets, simvastatin tablets, omeprazole sodium for injection and famotidine for injection, which treat infectious diseases such as pneumonia and bronchitis, hypertension, hypercholesterolemia and gastrointestinal conditions including ulcers and reflux esophagitis. Founded in 2005 and headquartered at Sanjiang Road, Paojiang Industrial Zone, Shaoxing, Zhejiang Province, China, the company primarily serves domestic and overseas markets in the healthcare sector with approximately 331 employees and operates through subsidiaries including Zhejiang Beide Pharmaceutical Co Ltd, whose pharmaceutical production license was recently updated. In September 2025, the company announces plans to acquire 100% equity of Zhangzhou Xipu Materials Technology Co Ltd, a producer of electronic-grade semiconductor materials, and the remaining 40% equity of Zhejiang Beide Pharmaceutical Co Ltd to make it wholly-owned, alongside raising supporting funds through share issuance and cash payments, marking a strategic expansion into high-tech industries beyond pharmaceuticals.